The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Lenvatinib in recurrent hepatocellular carcinoma after liver transplantation.
 
Mehmet Akce
Consulting or Advisory Role - AstraZeneca; Curio Science; Eisai; Eisai; Eisai; Eisai; Exelixis; Genentech; GlaxoSmithKline; Incyte; Ipsen; Isofol Medical; QED Therapeutics; Taiho Pharmaceutical
Research Funding - AstraZeneca (Inst); Bayer (Inst); Bellicum Pharmaceuticals (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb-Ono Pharmaceutical (Inst); Eisai (Inst); IMPAC Medical Systems (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst); Polaris (Inst); RedHill Biopharma (Inst); Syros Pharmaceuticals (Inst); Tesaro (Inst); Xencor (Inst)
 
Olumide B. Gbolahan
Stock and Other Ownership Interests - Pfizer
Consulting or Advisory Role - Exelixis; Incyte; Merck Sharp & Dohme; QED Therapeutics
Speakers' Bureau - OncLive/MJH Life Sciences
Research Funding - Astellas Pharma (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Eisai (Inst); Pfizer (Inst); Zymeworks (Inst)
 
Jeffrey M. Switchenko
No Relationships to Disclose
 
Mohamad B. Sonbol
No Relationships to Disclose
 
Giorgio Roccaro
No Relationships to Disclose
 
Robert M Cannon
No Relationships to Disclose
 
Saulat S Sheikh
No Relationships to Disclose
 
Olatunji B. Alese
Consulting or Advisory Role - AADi; Bristol-Myers Squibb; Pfizer; Seagen; Seagen; Taiho Oncology; Takeda
Research Funding - Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Corcept Therapeutics (Inst); GlaxoSmithKline (Inst); Hutchison MediPharma (Inst); Ipsen (Inst); PCI Biotech (Inst); SynCoreBio (Inst); Taiho Pharmaceutical (Inst); Transcenta (Inst)
 
Tanios S. Bekaii-Saab
Consulting or Advisory Role - Abbvie; Amgen (Inst); Arcus Biosciences (Inst); AstraZeneca; Bayer (Inst); BeiGene; Boehringer Ingelheim; Caladrius Biosciences; Caladrius Biosciences; Celularity; Daiichi Sankyo/UCB Japan; Deciphera; Eisai; Eisai; Exact Sciences; Foundation Medicine; Foundation Medicine; Illumina; Immuneering; Incyte (Inst); Ipsen (Inst); Janssen; Kanaph Therapeutics; Lilly (Inst); Natera; Pfizer (Inst); Roche/Genentech (Inst); Seagen (Inst); SOBI; Stemline Therapeutics; Treos Bio; Zai Lab
Patents, Royalties, Other Intellectual Property - Patent WO/2018/183488; Patent WO/2019/055687
Other Relationship - 1Globe Health Institute; AstraZeneca; Exelixis; FibroGen; Imugene; Lilly; Merck (Inst); Pancreatic Cancer Action Network; Replimune; Sun Biopharma; Suzhou Kintor Pharmaceuticals; UpToDate; Xilis
 
Bassel F. El-Rayes
Honoraria - Charles River Associates
Consulting or Advisory Role - AstraZeneca; Bristol Myers Squibb Foundation; Exelixis; Genentech; QED Therapeutics; QED Therapeutics; Seagen; Stemline Therapeutics; Taiho Oncology; Taiho Oncology
Speakers' Bureau - Intellisphere
Research Funding - Adaptimmune (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Boston Biomedical (Inst); Boston Biomedical (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Covance (Inst); Five Prime Therapeutics (Inst); Hoosier Cancer Research Network (Inst); ICON Clinical Research (Inst); IQvia (Inst); MedImmune (Inst); Merck (Inst); Merck (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Wayne State University (Inst); Xencor (Inst); Zymeworks (Inst)
Other Relationship - ERYTECH Pharma; Exelixis; SC Liver Research Consortium